Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT05259410

Time Restricted Eating During Chemotherapy for Breast Cancer

Sponsor: University of Illinois at Chicago

View on ClinicalTrials.gov

Summary

Breast cancer is the most common cancer in the United States however, little is known about how diet can affect cancer treatment. Pre-clinical murine studies report intermittent fasting increases effectiveness of chemotherapy and decreases treatment related adverse events. The proposed research will demonstrate that time restricted eating, a form of intermittent fasting, will improve treatment related outcomes, patient related outcomes, and limit treatment related weight gain and fat mass accretion.Time restricted eating combined with a mediterranean diet will also be feasible and improve cardiometabolic risk more than TRE alone or standard care.

Official title: The Safety and Efficacy of Time Restricted Eating Alone or Combined the Mediterranean Diet During Chemotherapy for Breast Cancer

Key Details

Gender

FEMALE

Age Range

25 Years - 99 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2022-08-01

Completion Date

2026-03-01

Last Updated

2025-10-01

Healthy Volunteers

Conditions

Breast Cancer Female

Interventions

BEHAVIORAL

TRE

All food eaten within the same self-selected 8 hour eating window daily, water fasting the remaining hours of the day.

BEHAVIORAL

MedTRE

A mediterranean style diet will be eaten within the same self-selected 8 hour eating window daily, water fasting the remaining hours of the day.

Inclusion Criteria: * Age 25-99 at time of consent * ECOG 0 or 1 * Breast cancer to meet histologically confirmed Stage I-III. * Demonstrates adequate organ function (absolutely neutrophil count ≥ 1,500/μL). * All screening labs to be obtained within 30 days prior to registration. * Able to provide written informed consent and HIPAA authorization for release of personal health information, via an approved UIC Institutional Review Board (IRB) informed consent form and HIPAA authorization. * Women of childbearing potential must not be pregnant or breast-feeding. A negative serum or urine pregnancy test is required per institutional practice guidelines. * As determined at the discretion of the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study. Exclusion Criteria: * Women with metastatic disease or type 1 or 2 diabetes * Women with BMI ≥ 40kg/m2 and \< 25kg/m2 * Women who are pregnant. A negative serum or urine pregnancy test is required per institutional practice guidelines. * Night shift workers * Women with a history of eating disorders * Enrolled participants with a significant weight loss or weight gain within 3 months of the study (weight gain or loss \>4kg) * Active infection requiring systemic therapy * Uncontrolled HIV/AIDS or active viral hepatitis * Pregnant or nursing * Any prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of this investigational regimen, as determined by the treating medical oncologist. * Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial. * Other major comorbidity, as determined by study PI * Illicit drug use or excessive use of alcohol (i.e., \> 2 drinks/day) * Currently participating in Weight Watcher's or another weight loss program * Myocardial infarction * Stroke * Congestive heart failure * Chronic hepatitis * Cirrhosis * Chronic pancreatitis * History of solid organ transplantation

Locations (1)

University of Illinois Chicago

Chicago, Illinois, United States